Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response.

Schepeler T, Lamy P, Hvidberg V, Laurberg JR, Fristrup N, Reinert T, Bartkova J, Tropia L, Bartek J, Halazonetis TD, Pan CC, Borre M, Dyrskjøt L, Orntoft TF.

Oncogene. 2013 Aug 1;32(31):3577-86. doi: 10.1038/onc.2012.381. Epub 2012 Aug 27.

PMID:
22926521
2.

High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.

Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M, Ruckert C, Huynh T, Liu G, Kato M, Sanada M, Jauch A, Dugas M, Black KL, Koeffler HP.

Mol Cancer Res. 2009 May;7(5):665-77. doi: 10.1158/1541-7786.MCR-08-0270. Epub 2009 May 12.

3.

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

Rebouissou S, Hérault A, Letouzé E, Neuzillet Y, Laplanche A, Ofualuka K, Maillé P, Leroy K, Riou A, Lepage ML, Vordos D, de la Taille A, Denoux Y, Sibony M, Guyon F, Lebret T, Benhamou S, Allory Y, Radvanyi F.

J Pathol. 2012 Jul;227(3):315-24. doi: 10.1002/path.4017. Epub 2012 May 8.

PMID:
22422578
4.

Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.

Korkolopoulou P, Givalos N, Saetta A, Goudopoulou A, Gakiopoulou H, Thymara I, Thomas-Tsagli E, Patsouris E.

Hum Pathol. 2005 Aug;36(8):899-907.

PMID:
16112007
5.
6.

Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.

Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F.

Cancer. 2004 Jun 1;100(11):2367-75.

7.

Frequent occurrence of uniparental disomy in colorectal cancer.

Andersen CL, Wiuf C, Kruhøffer M, Korsgaard M, Laurberg S, Ørntoft TF.

Carcinogenesis. 2007 Jan;28(1):38-48. Epub 2006 Jun 13.

PMID:
16774939
8.
9.

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.

Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP.

J Clin Oncol. 2004 Mar 15;22(6):1014-24. Epub 2004 Feb 23.

PMID:
14981102
10.

Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.

Balázs M, Carroll P, Kerschmann R, Sauter G, Waldman FM.

Genes Chromosomes Cancer. 1997 Jun;19(2):84-9.

PMID:
9171998
11.

Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.

Erill N, Colomer A, Verdú M, Román R, Condom E, Hannaoui N, Banús JM, Cordon-Cardo C, Puig X.

Diagn Mol Pathol. 2004 Dec;13(4):217-23.

PMID:
15538112
12.

Arecoline-induced phosphorylated p53 and p21(WAF1) protein expression is dependent on ATM/ATR and phosphatidylinositol-3-kinase in clone-9 cells.

Chou WW, Guh JY, Tsai JF, Hwang CC, Chiou SJ, Chuang LY.

J Cell Biochem. 2009 Jun 1;107(3):408-17. doi: 10.1002/jcb.22137.

PMID:
19343784
13.

High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors.

Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Møller K, von der Maase H, Orntoft TF.

Cancer Res. 2005 Jan 1;65(1):34-45.

14.

Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder.

Youssef RF, Shariat SF, Kapur P, Kabbani W, Ghoneim T, King E, Cockburn A, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y.

Hum Pathol. 2011 Mar;42(3):347-55. doi: 10.1016/j.humpath.2010.07.012. Epub 2010 Nov 26.

PMID:
21111452
15.

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J.

Nature. 2005 Apr 14;434(7035):864-70.

PMID:
15829956
16.

A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.

Tsai MF, Wang CC, Chang GC, Chen CY, Chen HY, Cheng CL, Yang YP, Wu CY, Shih FY, Liu CC, Lin HP, Jou YS, Lin SC, Lin CW, Chen WJ, Chan WK, Chen JJ, Yang PC.

J Natl Cancer Inst. 2006 Jun 21;98(12):825-38.

PMID:
16788156
17.

Overexpression of CDCA2 in human squamous cell carcinoma: correlation with prevention of G1 phase arrest and apoptosis.

Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, Shiiba M, Bukawa H, Tanzawa H.

PLoS One. 2013;8(2):e56381. doi: 10.1371/journal.pone.0056381. Epub 2013 Feb 13.

18.

Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer.

Zieger K, Wiuf C, Jensen KM, Ørntoft TF, Dyrskjøt L.

BMC Cancer. 2009 May 16;9:149. doi: 10.1186/1471-2407-9-149.

19.

Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco JC, Requena MJ, Montironi R.

Eur Urol. 2004 May;45(5):606-12.

PMID:
15082203
20.

ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity.

Angèle S, Romestaing P, Moullan N, Vuillaume M, Chapot B, Friesen M, Jongmans W, Cox DG, Pisani P, Gérard JP, Hall J.

Cancer Res. 2003 Dec 15;63(24):8717-25.

Supplemental Content

Support Center